Basel, 2018-10-29 - NBE-Therapeutics was invited to present at Terrapinn's 2018 European Antibody Congress
Ulf Grawunder, CEO of NBE-Therapeutics, was invited to provide an update on NBE-Therapeutics ADC development activities at Terrapinn's European Antibody Congress, which is part of the 2018 Festival of Biologics
NBE-Therapeutics was invited for a presentation and for chairing of the Technology Showcase at Terrapinn's 2018 Festival of Biologics, which include the European Antibody Congress, the World Immunotherapy congress and the High-potency API congress. Ulf's presentation took place in the ADC stream of the European Antibody Congress on Tuesday, Oct 30, 2:30 p.m. and was entitled "Novel immune-stimulatory ADCs (iADCs) for effective targeting of solid tumors". In his presentation, Ulf presented for the first time the concept of the strong immune-stimulatory function of NBE's iADCs that can trigger a long-lasting anti-tumor immunity in syngeneic mouse tumor models.
Recent news feed
RSS feed from: